TITLE

Clopidogrel: A Pharmacogenomic Perspective on its Use in Coronary Artery Disease

AUTHOR(S)
Terpening, Chris
PUB. DATE
January 2010
SOURCE
Clinical Medicine Insights: Cardiology;2010, Issue 4, p117
SOURCE TYPE
Academic Journal
DOC. TYPE
Article
ABSTRACT
The thienopyridine antiplatelet agent clopidogrel is an effective drug for the prevention of vascular events. However, data has accumulated over time to suggest it is prone to significant interpatient variability. While there are several factors that contribute to this, one of the most important is variability in forming the active metabolite necessary for clopidogrel function. Several enzymes are involved in formation of this metabolite, and two, CYP2C19 and P-glycoprotein, appear to have alleles that both occur frequently in the population and have a clinically significant impact. Patients carrying these alleles can be identified, but it remains to be determined if this information is necessary or sufficient for risk stratification. Furthermore, if patients with high-risk alleles are identified, it is unclear how treatment should be adjusted.
ACCESSION #
57521019

 

Related Articles

  • Antiplatelet Therapy in Patients Undergoing Percutaneous Coronary Intervention: Economic Considerations. Weintraub, William S.; Mandel, Leonid; Weiss, Sandra A. // PharmacoEconomics;Nov2013, Vol. 31 Issue 11, p959 

    Percutaneous coronary intervention (PCI) is one of the most common medical procedures performed for treatment of coronary artery disease. Antiplatelet medications as adjunctive therapy for PCI are used routinely, with indications for specific agents or their combinations varying depending on the...

  • Ticagrelor provides improved survival, similar QOL in ACS.  // PharmacoEconomics & Outcomes News;7/1/2013, Issue 682, p10 

    The article discusses a research on the treatment of acute coronary syndromes, in reference to the study "Health-Related Quality of Life of Ticagrelor versus Clopidogrel in Patients with Acute Coronary Syndromes-Results from the PLATO Trial," by L. A. Levin, et al, in the June 2013 issue of...

  • Inhibitori receptora P2Y12 u liječenju koronarne bolesti srca -- izazovi i perspektiva u optimizaciji antitrombocitnog liječenja. Samardžić, Jure // Cardiologia Croatica;Sep/Oct2014, Vol. 9 Issue 9/10, p346 

    Antiplatelet drugs have a fundamental role in acute and chronic pharmacotherapy of coronary artery disease (CAD) as they reduce the risk of ischemic cardiac and cerebrovascular events. Clopidogrel is the most used P2Y12 receptor inhibitor despite it's very variable effect caused by different...

  • JournalScan. Lindsay, Alistair // Heart;May2010, Vol. 96 Issue 9, p729 

    The article discusses the results of the Platelet inhibition and patient Outcomes (PLATO) trial on the effectiveness of ticagrelor in treating patients with an acute coronary syndrome. According to the author, the PLATO trial demonstrates the superiority of ticagrelor over clopidogrel. The...

  • Effects of hypoxia and limited diffusion in tumor cell microenvironment on bystander effect of P450 prodrug therapy. Günther, M.; Waxman, D. J.; Wagner, E.; Ogris, M. // Cancer Gene Therapy;Aug2006, Vol. 13 Issue 8, p771 

    Cytochrome P450 (CYP) enzyme 2B1 metabolizes the anticancer prodrug cyclophosphamide (CPA) to 4-hydroxy-CPA, which decomposes to the cytotoxic metabolites acrolein and phosphoramide mustard. We have evaluated the bystander cytotoxicity of CPA in combination with CYP2B1 gene-directed enzyme...

  • Ticagrelor � Is There Need for a New Player in the Antiplatelet-Therapy Field? Sch�mig, Albert // New England Journal of Medicine;9/10/2009, Vol. 361 Issue 11, p1108 

    In this article, the author expresses his views on the effectiveness of ticagrelor as an antiplatelet therapy, in relation to a study published in a 2009 issue of the journal "New England Journal of Medicine." He mentions the impact of thienopyridine clopidogrel on therapy in patients with acute...

  • Ticagrelor: An oral, non-thienopyridine P2Y12 receptor antagonist for the treatment of acute coronary syndromes. Jennings, Douglas L. // Formulary;May2010, Vol. 45 Issue 5, p148 

    Coronary heart disease and acute coronary syndromes (ACS) are a significant cause of morbidity and mortality in the United States. The cornerstone of ACS management is combination oral antiplatelet therapy, usually with aspirin and a thienopyridine. Clopidogrel, the most commonly used...

  • Monitoring Aspirin and Clopidogrel Response: Testing Controversies and Recommendations. Karathanos, Athanasios; Geisler, Tobias // Molecular Diagnosis & Therapy;Jun2013, Vol. 17 Issue 3, p123 

    Antiplatelet therapy is the cornerstone of the treatment for patients with coronary artery disease (CAD). Dual therapy with clopidogrel and aspirin is currently the standard treatment after percutaneous coronary interventions. However, despite the use of clopidogrel, a considerable number of...

  • Triple versus Dual Antiplatelet Therapy in Acute Coronary Syndromes: Adding Cilostazol to Aspirin and Clopidogrel? Niazi, asfandyar K.; DiNicolantonio, James J.; Lavie, Carl J.; O'Keefe, James H.; Meier, Pascal; Bangalore, Sripal // Cardiology;Nov2013, Vol. 126 Issue 4, p233 

    Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 receptor antagonist is the standard of care in acute coronary syndromes. Additionally, novel P2Y12 receptor antagonists such as prasugrel and ticagrelor are even recommended over clopidogrel in certain clinical guidelines. Despite the...

Share

Read the Article

Courtesy of THE LIBRARY OF VIRGINIA

Sorry, but this item is not currently available from your library.

Try another library?
Sign out of this library

Other Topics